期刊
DEPRESSION AND ANXIETY
卷 27, 期 6, 页码 495-506出版社
WILEY
DOI: 10.1002/da.20699
关键词
obsessive-compulsive disorder; anxiety disorder; obsessive-compulsive spectrum disorder; classification; nosology
资金
- Astrazeneca
- GlaxoSmithKline
- Jazz Pharmaceuticals
- Johnson & Johnson, Lundbeck
- Orion
- Pfizer
- Pharmacia
- Roche
- Servier
- Solvay
- Sumitomo
- Takeda
- Tikvah
- Wyeth
- NATIONAL INSTITUTE OF MENTAL HEALTH [K24MH063975] Funding Source: NIH RePORTER
In DSM-III, DSM-III-R, and DSM-IV obsessive-compulsive disorder (OCD) was classified as an anxiety disorder. In ICD-10, OD is classified separately from the anxiety disorders, although within the same larger category as anxiety disorders (as one of the neurotic, stress-related, and somatoform disorders). Ongoing advances in our understanding of OCD and other anxiety disorders have raised the question of whether OD should continue to be classified with the anxiety disorders in DSM-V This review presents a number of options and preliminary recommendations to be considered for DSM-V Evidence is reviewed for retaining OCD in the category of anxiety disorders, and for moving OCD to a separate category of obsessive-compulsive (OC)-spectrum disorders, if such a category is included in DSM-V Our preliminary recommendation is that OCD be retained in the category of anxiety disorders but that this category also includes OC-spectrum disorders along with OCD. If this change is made, the name of this category should be changed to reflect this proposed change. Depression and Anxiety 27:495-506, 2010. (C) 2010 Wiley-Liss, Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据